Skip to content
Bending the Curve Trial by Trial
?

Back to Multiple myeloma

References: Multiple myeloma

158 sources cited on this page. Links open the primary source.

  1. Solly S. Remarks on the pathology of mollities ossium; with cases. Med Chir Trans. 1844;27:435-498.8. PubMedDOI
    CiteLoading…
  2. Dalrymple J. On the microscopical character of mollities ossium. Dublin Quarterly Journal of Medical Science. 1846;2(1):85-95. DOI
    CiteLoading…
  3. Jones HB. On a new substance occurring in the urine of a patient with mollities ossium. Philosophical Transactions of the Royal Society of London. 1848;138:55-62. DOI
    CiteLoading…
  4. Jones HB. Some Account of a New Animal Substance Occurring in the Urine of a Patient Labouring under Mollities Ossium. Edinb Med Surg J. 1850;74(185):357-368. PubMed
    CiteLoading…
  5. Macintyre W. Case of Mollities and Fragilitas Ossium, accompanied with urine strongly charged with animal matter. Med Chir Trans. 1850;33:211-32. PubMedDOI
    CiteLoading…
  6. Macintyre W. Case of Mollities and Fragilitas Ossium, Accompanied with Urine Strongly Charged with Animal Matter. Edinb Med Surg J. 1851;75(186):157-173. PubMed
    CiteLoading…
  7. BERGSAGEL DE, SPRAGUE CC, AUSTIN C, GRIFFITH KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep. 1962;21:87-99. PubMed
    CiteLoading…
  8. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208(9):1680-5. PubMedDOI
    CiteLoading…
  9. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-54. PubMedDOI
    CiteLoading…
  10. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2(8354):822-4. PubMedDOI
    CiteLoading…
  11. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335(2):91-7. PubMedDOI
    CiteLoading…
  12. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16(12):3832-42. PubMedDOI
    CiteLoading…
  13. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565-71. PubMedDOI
    CiteLoading…
  14. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495-502. PubMedDOI
    CiteLoading…
  15. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875-83. PubMedDOI
    CiteLoading…
  16. US Food and Drug Administration. Approved labeling, NDA 21-602, Velcade (bortezomib) for Injection, Millennium Pharmaceuticals, Inc.; package insert finalised 13 May 2003 (Indications and Usage section). Source
  17. US Food and Drug Administration. Approval letter, NDA 21-602, Velcade (bortezomib) for Injection, Millennium Pharmaceuticals, Inc.; electronically signed 13 May 2003 (R Temple, Office of Drug Evaluation 1). Source
  18. Harousseau JL. Traitement intensif du myélome multiple. Académie nationale de médecine, séance du 25 février 2003. Source
  19. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609-17. PubMedDOI
    CiteLoading…
  20. US Food and Drug Administration. Supplement approval letter, NDA 21-602/S-006, Velcade (bortezomib) for Injection, Millennium Pharmaceuticals, Inc.; electronically signed 25 March 2005 (R Pazdur, Division of Oncology Drug Products). Source
  21. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20. PubMedDOI
    CiteLoading…
  22. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487-98. PubMedDOI
    CiteLoading…
  23. US Food and Drug Administration. Supplement approval letter, NDA 21-880/S-001, Revlimid (lenalidomide) capsules, Celgene Corporation; letter signed 29 June 2006. Source
  24. US Food and Drug Administration. Approval letter, NDA 21-430 and NDA 20-785/S-031, Thalomid (thalidomide) capsules, Celgene Corporation; letter signed 25 May 2006. Source
  25. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer. 2006;106(6):1316-9. PubMedDOI
    CiteLoading…
  26. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-32. PubMedDOI
    CiteLoading…
  27. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-18. PubMedDOI
    CiteLoading…
  28. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557-60. PubMedDOI
    CiteLoading…
  29. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133-42. PubMedDOI
    CiteLoading…
  30. Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26(13):2171-7. PubMedDOI
    CiteLoading…
  31. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-17. PubMedDOI
    CiteLoading…
  32. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259-66. PubMedDOI
    CiteLoading…
  33. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37. PubMedDOI
    CiteLoading…
  34. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-91. PubMedDOI
    CiteLoading…
  35. U.S. Food and Drug Administration. Accelerated approval letter, NDA 202714 (Kyprolis, carfilzomib). 20 July 2012. Source
  36. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81. PubMedDOI
    CiteLoading…
  37. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817-25. PubMedDOI
    CiteLoading…
  38. Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438-47. PubMedDOI
    CiteLoading…
  39. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906-17. PubMedDOI
    CiteLoading…
  40. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. PubMedDOI
    CiteLoading…
  41. U.S. Food and Drug Administration. Replacement approval letter, BLA 761036 (Darzalex, daratumumab). Effective approval date 16 November 2015; signed 16 November 2015. Source
  42. U.S. Food and Drug Administration. Supplement approval letter, NDA 202714/S-009 (Kyprolis with lenalidomide and dexamethasone; fulfilment of postmarketing requirement PMR 1908-1). 24 July 2015. Source
  43. US Food and Drug Administration. Supplement approval letter, NDA 021880/S-041, Revlimid (lenalidomide) capsules, Celgene Corporation; letter signed 17 February 2015. Source
  44. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015;373(13):1207-19. PubMedDOI
    CiteLoading…
  45. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9. PubMedDOI
    CiteLoading…
  46. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-52. PubMedDOI
    CiteLoading…
  47. Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105(2):140-56. PubMedDOI
    CiteLoading…
  48. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27-38. PubMedDOI
    CiteLoading…
  49. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(14):1319-1331. PubMedDOI
    CiteLoading…
  50. U.S. Food and Drug Administration. Supplement approval letter, BLA 761036/S-003 (Darzalex with lenalidomide and dexamethasone; fulfilment of postmarketing requirement). 21 November 2016. Source
  51. U.S. Food and Drug Administration. Supplement approval letter, BLA 761036/S-004 (Darzalex with bortezomib and dexamethasone; fulfilment of postmarketing requirement). 21 November 2016. Source
  52. U.S. Food and Drug Administration. Supplement approval letter, NDA 202714/S-010 (Kyprolis; regular approval of the monotherapy indication based on ENDEAVOR; Subpart H fulfilled). 21 January 2016. Source
  53. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. PubMedDOI
    CiteLoading…
  54. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-1560. PubMedDOI
    CiteLoading…
  55. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(8):754-66. PubMedDOI
    CiteLoading…
  56. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376(14):1311-1320. PubMedDOI
    CiteLoading…
  57. Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519-527. PubMedDOI
    CiteLoading…
  58. US Food and Drug Administration. Supplement approval letter, NDA 021880/S-049, Revlimid (lenalidomide) capsules, Celgene Corporation; letter signed 22 February 2017. Source
  59. McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017;35(29):3279-3289. PubMedDOI
    CiteLoading…
  60. Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017;3(1):28-35. PubMedDOI
    CiteLoading…
  61. Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301-310. PubMedDOI
    CiteLoading…
  62. U.S. Food and Drug Administration. Supplement approval letter, BLA 761036/S-013 (Darzalex with bortezomib, melphalan and prednisone, newly diagnosed, transplant-ineligible). 7 May 2018. Source
  63. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018;378(6):518-528. PubMedDOI
    CiteLoading…
  64. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096-2107. PubMedDOI
    CiteLoading…
  65. Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380(22):2104-2115. PubMedDOI
    CiteLoading…
  66. U.S. Food and Drug Administration. Supplement approval letter, BLA 761036/S-020 (Darzalex with lenalidomide and dexamethasone, newly diagnosed, transplant-ineligible). 27 June 2019. Source
  67. U.S. Food and Drug Administration. Supplement approval letter, BLA 761036/S-024 (Darzalex with bortezomib, thalidomide and dexamethasone, newly diagnosed, transplant-eligible). 26 September 2019. Source
  68. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29-38. PubMedDOI
    CiteLoading…
  69. U.S. Food and Drug Administration. Approval letter, BLA 761113 (Sarclisa, isatuximab-irfc). 2 March 2020. Source
  70. Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317-1330. PubMedDOI
    CiteLoading…
  71. Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630-1642. PubMedDOI
    CiteLoading…
  72. Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2020;38(11):1126-1137. PubMedDOI
    CiteLoading…
  73. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207-221. PubMedDOI
    CiteLoading…
  74. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936-945. PubMedDOI
    CiteLoading…
  75. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. PubMedDOI
    CiteLoading…
  76. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(†). Ann Oncol. 2021;32(3):309-322. PubMedDOI
  77. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Hemasphere. 2021;5(2):e528. PubMedDOI
  78. U.S. Food and Drug Administration, CBER. Approval letter, BLA 125736 (Abecma, idecabtagene vicleucel). 26 March 2021. Source
  79. U.S. Food and Drug Administration. Supplement approval letter, BLA 761113/S-003 (Sarclisa with carfilzomib and dexamethasone). 31 March 2021. Source
  80. Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361-2371. PubMedDOI
    CiteLoading…
  81. Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705-716. PubMedDOI
    CiteLoading…
  82. Sewpersad S, Pillay TS. Historical perspectives in clinical pathology: Bence Jones protein-early urine chemistry and the impact on modern day diagnostics. J Clin Pathol. 2021;74(4):212-215. PubMedDOI
    CiteLoading…
  83. Baines AC, Ershler R, Kanapuru B, Xu Q, Shen G, Li L, et al. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2022;28(21):4629-4633. PubMedDOI
    CiteLoading…
  84. Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387(24):2232-2244. PubMedDOI
    CiteLoading…
  85. D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40(29):3406-3418. PubMedDOI
    CiteLoading…
  86. U.S. Food and Drug Administration, CBER. Approval letter, BLA 125746 (Carvykti, ciltacabtagene autoleucel). 28 February 2022. Source
  87. U.S. Food and Drug Administration. Accelerated approval letter, BLA 761291 (Tecvayli, teclistamab-cqyv). 25 October 2022. Source
  88. Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9(11):e810-e821. PubMedDOI
    CiteLoading…
  89. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495-505. PubMedDOI
    CiteLoading…
  90. Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022;387(2):132-147. PubMedDOI
    CiteLoading…
  91. Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801-e812. PubMedDOI
    CiteLoading…
  92. European Medicines Agency. EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep. News item, 15 September 2023. Source
  93. U.S. Food and Drug Administration. Revocation of the biologics license for Blenrep (belantamab mafodotin-blmf); notice. Federal Register 88(61):19153, 30 March 2023 (FR Doc. 2023-06576, Docket FDA-2023-N-0964). Source
  94. U.S. Food and Drug Administration. Accelerated approval letter, BLA 761345 (Elrexfio, elranatamab-bcmm). 14 August 2023. Source
  95. U.S. Food and Drug Administration. Accelerated approval letter, BLA 761342 (Talvey, talquetamab-tgvs). 9 August 2023. Source
  96. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259-2267. PubMedDOI
    CiteLoading…
  97. Ludwig H, Kainz S, Schreder M, Zojer N, Hinke A. SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of 'biomarker-defined early multiple myeloma'-a systematic review with meta-analysis. EClinicalMedicine. 2023;58:101910. PubMedDOI
    CiteLoading…
  98. Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023;388(11):1002-1014. PubMedDOI
    CiteLoading…
  99. San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389(4):335-347. PubMedDOI
    CiteLoading…
  100. Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, et al. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024;42(22):2702-2712. PubMedDOI
    CiteLoading…
  101. Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N Engl J Med. 2024;391(5):408-421. PubMedDOI
    CiteLoading…
  102. Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;391(17):1597-1609. PubMedDOI
    CiteLoading…
  103. U.S. Food and Drug Administration, CBER. Supplement approval letter, Abecma (idecabtagene vicleucel): indication after two or more prior lines of therapy. 4 April 2024. Source
  104. U.S. Food and Drug Administration, CBER. Supplement approval letter, Carvykti (ciltacabtagene autoleucel): indication extended on the basis of CARTITUDE-4. 5 April 2024. Source
  105. U.S. Food and Drug Administration. Supplement approval letter, BLA 761145/S-025 (Darzalex Faspro with bortezomib, lenalidomide and dexamethasone, induction and consolidation, transplant-eligible). 30 July 2024. Source
  106. U.S. Food and Drug Administration. Supplement approval letter, BLA 761113/S-014 (Sarclisa with bortezomib, lenalidomide and dexamethasone, newly diagnosed, not eligible for ASCT). 20 September 2024. Source
  107. US Food and Drug Administration. Summary minutes of the Oncologic Drugs Advisory Committee meeting, April 12, 2024. Source
  108. Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;391(5):393-407. PubMedDOI
    CiteLoading…
  109. Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390(4):301-313. PubMedDOI
    CiteLoading…
  110. Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, et al. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. N Engl J Med. 2025;392(18):1777-1788. PubMedDOI
    CiteLoading…
  111. Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, et al. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22(9):680-700. PubMedDOI
  112. Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, et al. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025;39(4):942-950. PubMedDOI
    CiteLoading…
  113. U.S. Food and Drug Administration, CBER. Supplement approval letter, Abecma (idecabtagene vicleucel): modification of the REMS to eliminate it. 26 June 2025. Source
  114. U.S. Food and Drug Administration. Approval letter, BLA 761440/Original 1 (Blenrep, belantamab mafodotin-blmf, with bortezomib and dexamethasone). Electronically signed 23 October 2025. Source
  115. U.S. Food and Drug Administration, CBER. Supplement approval letter, Carvykti (ciltacabtagene autoleucel): second interim analysis of CARTITUDE-4 including overall survival; boxed warning and safety updates. 10 October 2025. Source
  116. U.S. Food and Drug Administration, CBER. Supplement approval letter, Carvykti (ciltacabtagene autoleucel): modification of the REMS to eliminate it. 26 June 2025. Source
  117. U.S. Food and Drug Administration. Accelerated approval letter, BLA 761400 (Lynozyfic, linvoseltamab). 2 July 2025. Source
  118. US Food and Drug Administration. Supplement approval letter, Darzalex Faspro (daratumumab and hyaluronidase-fihj), BLA 761145/S-029, Janssen Biotech; electronic signature date 6 November 2025. Source
  119. Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study. Lancet Haematol. 2025;12(8):e574-e587. PubMedDOI
    CiteLoading…
  120. Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025;31(4):1195-1202. PubMedDOI
    CiteLoading…
  121. Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, et al. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2026;394(8):739-752. PubMedDOI
    CiteLoading…
  122. Cancer Research UK. Myeloma survival statistics (health professional pages, UK cancer statistics). Page accessed 21 October 2026; the page displays no update date. Source
  123. ClinicalTrials.gov. NCT04923893 (CARTITUDE-5). Registry record, API v2, accessed 21 October 2026. NCT04923893
  124. ClinicalTrials.gov. NCT05020236 (MagnetisMM-5). Registry record, API v2, accessed 21 October 2026. NCT05020236
  125. ClinicalTrials.gov. NCT05243797 (MajesTEC-4). Registry record, API v2, accessed 21 October 2026. NCT05243797
  126. ClinicalTrials.gov. NCT05257083 (CARTITUDE-6). Registry record, API v2, accessed 21 October 2026. NCT05257083
  127. ClinicalTrials.gov. NCT05552222 (MajesTEC-7). Registry record, API v2, accessed 21 October 2026. NCT05552222
  128. ClinicalTrials.gov. NCT06413498 (iMMagine-3). Registry record, API v2, accessed 21 October 2026. NCT06413498
  129. Dimopoulos MA, Hungria V, Meng H, Radinoff A, Li J, Delimpasi S, et al. Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J. 2026;16(1). PubMedDOI
    CiteLoading…
  130. Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW, et al. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2026;27(2):254-268. PubMedDOI
    CiteLoading…
  131. European Medicines Agency. Abecma: EPAR overview page. Accessed 21 October 2026. Source
  132. European Medicines Agency. Blenrep (conditional marketing authorisation of 25 August 2020, expired): EPAR overview page. Accessed 21 October 2026. Source
  133. European Medicines Agency. Blenrep (marketing authorisation of 23 July 2025): EPAR overview page. Accessed 21 October 2026. Source
  134. European Medicines Agency. Carvykti: EPAR overview page. Accessed 21 October 2026. Source
  135. European Medicines Agency. Darzalex: EPAR (European public assessment report) overview page. Accessed 21 October 2026. Source
  136. European Medicines Agency. Elrexfio: EPAR overview page. Accessed 21 October 2026. Source
  137. European Medicines Agency. Kyprolis: EPAR overview page. Accessed 21 October 2026. Source
  138. European Medicines Agency. Lynozyfic: EPAR overview page. Accessed 21 October 2026. Source
  139. European Medicines Agency. Medicines output: medicines data file (JSON report), fields including conditional_approval, marketing_authorisation_date and therapeutic_indication as printed. Downloaded 21 October 2026. Source
  140. European Medicines Agency. Revlimid (lenalidomide): European public assessment report page; marketing authorisation issued 14 June 2007 (page shows 14/06/2007). Source
  141. European Medicines Agency. Sarclisa: EPAR overview page. Accessed 21 October 2026. Source
  142. European Medicines Agency. Talvey: EPAR overview page. Accessed 21 October 2026. Source
  143. European Medicines Agency. Tecvayli: EPAR overview page. Accessed 21 October 2026. Source
  144. European Medicines Agency. Velcade (bortezomib): European public assessment report page; marketing authorisation issued 26 April 2004 (page shows 26/04/2004). Source
  145. European Medicines Agency. Venclyxto (venetoclax): European public assessment report (EPAR) page. Marketing authorisation issued 04/12/2016 (the page lists a combination with a hypomethylating agent for newly diagnosed AML among the indications but shows no date for that indication; the date is in the procedural-steps document). Page read 2026-10-21. Source
  146. U.S. Food and Drug Administration. Supplement approval letter, BLA 761145/S-028 (Darzalex Faspro with bortezomib, lenalidomide and dexamethasone, newly diagnosed, transplant-ineligible). 27 January 2026. Source
  147. U.S. Food and Drug Administration. Supplement approval letter, BLA 761291/S-018 (Tecvayli: conversion to traditional approval for monotherapy; new indication with daratumumab hyaluronidase-fihj). 5 March 2026. Source
  148. U.S. Food and Drug Administration. Accelerated approval letter, NDA 221075, Zenbexus (iberdomide) capsules, Bristol-Myers Squibb Company; signed 13 August 2026. Read 21 October 2026. Source
  149. US Food and Drug Administration. Minimal residual disease and complete response in multiple myeloma: use as endpoints to support accelerated approval. Draft guidance for industry. January 2026. Source
  150. FDA. Ongoing | Cancer Accelerated Approvals. Listing, content current as of 19 October 2026 (accessed 20 October 2026). Source
  151. US Food and Drug Administration. Verified Clinical Benefit | Cancer Accelerated Approvals. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Content current as of 16 October 2026. Source
  152. FDA. Withdrawn | Cancer Accelerated Approvals. Listing, content current as of 5 October 2026 (accessed 19 October 2026). Source
  153. Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, et al. Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026;24(1). PubMedDOI
  154. Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A, et al. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. N Engl J Med. 2026;395(3):221-232. PubMedDOI
    CiteLoading…
  155. Mina R, Beksac M, Rodríguez-Otero P, Chen W, Mateos MV, Li J, et al. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. N Engl J Med. 2026;395(7):671-683. PubMedDOI
    CiteLoading…
  156. Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, et al. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. J Clin Oncol. 2026;44(3):164-175. PubMedDOI
    CiteLoading…
  157. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Myeloma. Page accessed 21 October 2026; the page displays no update date (its HTML last_modified tag reads 22 April 2026). Source
  158. Touzeau C, Mina R, Quach H, Hungria V, Bhutani D, Chen W, et al. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. N Engl J Med. 2026;395(5):440-453. PubMedDOI
    CiteLoading…